ATYR250117C5000
- 0.05
- 0.000.00%
aTyr Pharma Newsroom
ATyr Pharma, Inc. (NASDAQ:ATYR) Is a Favorite Amongst Institutional Investors Who Own 57%
ATyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Express News | ATyr Pharma Announces the Appointment of Eric Benevich to Its Board of Directors
JonesTrading Maintains ATyr Pharma(ATYR.US) With Buy Rating, Maintains Target Price $22
H.C. Wainwright Maintains ATyr Pharma(ATYR.US) With Buy Rating, Maintains Target Price $35
Positive Outlook for ATyr Pharma: Favorable Phase 3 Progress and Competitive Advantage Highlight Buy Rating
Express News | ATyr Pharma Inc: Dsmb Recommended That Study Continue Without Any Modifications
Express News | ATyr Pharma Announces Third Positive Dsmb Review for Efzofitimod in Phase 3 Efzo-Fit™ Study in Pulmonary Sarcoidosis
ATyr Pharma To Present Preclinical Research Demonstrating Anti-Fibrotic Effects Of ATYR0101 In Lung and Kidney Fibrosis At Keystone Symposia On Fibrosis
ATyr Pharma's Strategic Advantage and Promising Developments in Pulmonary Sarcoidosis Treatment
ATyr Pharma Price Target Maintained With a $35.00/Share by HC Wainwright & Co.
Is ATyr Pharma, Inc. (ATYR) the Best Multibagger Stock to Buy Heading Into 2025?
ATyr Pharma To Present Poster SOn ATYR0101 At Keystone Symposia on Fibrosis Dec. 8-11
RBC Capital Maintains ATyr Pharma(ATYR.US) With Buy Rating, Maintains Target Price $16
RBC Capital Sticks to Its Buy Rating for ATyr Pharma (ATYR)
ATyr Pharma Reports Q3 2024 Financial Results
JonesTrading Initiates ATyr Pharma(ATYR.US) With Buy Rating, Announces Target Price $22
Promising Clinical Advancements and Strong Financial Health Drive Buy Rating for ATyr Pharma
ATyr Pharma Q3 2024 GAAP EPS $(0.23) Misses $(0.22) Estimate
aTyr Pharma | 10-Q: Q3 2024 Earnings Report